Company Overview
Company Type: Private Company
Website: www.viricabiotech.com
Number of Employees: -
Year Founded: 2018
Total Amount Raised (CAD mm)†: 5.17
Total Rounds of Funding**:3
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Virica Biotech Inc. develops life science solutions for scaling viral medicines. It provides Viral Sensitizers, the small molecules technology that improves viral yields and effectiveness by reducing the antiviral defenses on a cellular level. The company has a collaboration with the National Research Council of Canada. Virica Biotech Inc. was incorporated in 2018 and is based in Ottawa, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Newport, Ken 
Executive Chairman
Diallo, Jean-Simon 
Scientific Founder & CEO
Korets-Smith, Ella 
Co-Founder & Chief Strategy Officer
Miron, Patrick 
Director of Operations
De Jong, JonDavid 
Vice President of Scientific Operations
Casey, Paul 
Vice President of Sales
Thompson-Webb, Beth 
Chief Commercial Officer

Key Board Members
Name
Title
Newport, Ken 
Executive Chairman


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
7 Bayview Station Road | Ottawa, ON | K1Y 2C5 | Canada
Phone: 613-737-8899   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Dynamk Capital LLC
Oct-04-2021
Minority
-
Series A


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-25-2022
Jun-16-2022
Private Placement
Target
Virica Biotech Inc.


0.50
Oct-04-2021
-
Private Placement
Target
Virica Biotech Inc.
Dynamk Capital LLC

-
Sep-27-2021
Nov-19-2021
Private Placement
Target
Virica Biotech Inc.


3.50
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Apr-25-2023
Company Conference Presentations
Virica Biotech Inc. Presents at 2023 Bloom Burton & Co. Healthcare Investor Conference, Apr-25-2023 10:00 AM
Jan-05-2023
Executive/Board Changes - Other
Virica Biotech Inc. Appoints Beth Thompson-Webb as Chief Commercial Officer, Effective on January 9, 2023
Oct-13-2022
Company Conference Presentations
Virica Biotech Inc. Presents at World Vaccine Congress Europe 2022, Oct-13-2022 03:15 PM
Jun-16-2022
Private Placements
Virica Biotech Inc. announced that it has received $0.499999 million in funding
May-02-2022
Company Conference Presentations
Virica Biotech Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, May-02-2022 02:30 PM


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 09:30 PM
Virica Biotech Inc.
Virica Biotech Inc
Reports
34
GlobalData

Jun 29, 2023 12:21 AM
Virica Biotech Inc.
Virica Biotech Inc
Reports
35
GlobalData

Mar 28, 2023 03:19 AM
Virica Biotech Inc.
Virica Biotech Inc
Reports
35
GlobalData

Dec 14, 2022 03:56 AM
Virica Biotech Inc.
Virica Biotech Inc
Reports
32
GlobalData

Sep 20, 2022 08:08 AM
Virica Biotech Inc.
Virica Biotech Inc
Reports
32
GlobalData

Jun 18, 2022 03:31 AM
Virica Biotech Inc.
Virica Biotech Inc
Reports
30
GlobalData

Mar 15, 2022 05:09 AM
Virica Biotech Inc.
Virica Biotech Inc
Reports
30
GlobalData

Dec 15, 2021 02:28 AM
Virica Biotech Inc.
Virica Biotech Inc
Reports
29


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Newport, Ken 
Executive Chairman
613-737-8899
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Newport, Ken 
Executive Chairman
613-737-8899
-

Diallo, Jean-Simon 
Scientific Founder & CEO
613-737-8899
-

Korets-Smith, Ella 
Co-Founder & Chief Strategy Officer
613-737-8899
-
eksmith@viricabiotech.com
Miron, Patrick 
Director of Operations
613-737-8899
-

De Jong, JonDavid 
Vice President of Scientific Operations
613-737-8899
-

Casey, Paul 
Vice President of Sales
613-737-8899
-

Thompson-Webb, Beth 
Chief Commercial Officer
613-737-8899
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
